A recent study reveals that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle programs.
Findings released in a major health publication shows that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these treatments need to be cognizant of the potential of quick weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to original mass in about a year and a half.
Weighing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
The team note that people who lose weight through dieting generally experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors believe the way of the jabs is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Disease?
Health authorities suggest the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the therapy is often long-term.
This perspective is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic character of obesity," akin to managing conditions like high blood pressure.
User Testimonies
Individuals who have discontinued the medication report a intense resurgence of cravings.
"I experienced something activating and you become ravenous," described one woman.
This difficulty is exacerbated if users have not established lasting dietary or behavioural modifications during therapy.
Significant Interest
Figures show that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Use is more common among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a magic solution and long-term success hinges on combined lifestyle changes.
